Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations
Identifieur interne : 000775 ( Main/Corpus ); précédent : 000774; suivant : 000776Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations
Auteurs : Carlo Colosimo ; Pablo Martínez-Martín ; Giovanni Fabbrini ; Robert A. Hauser ; Marcelo Merello ; Janis Miyasaki ; Werner Poewe ; Cristina Sampaio ; Olivier Rascol ; Glenn T. Stebbins ; Anette Schrag ; Christopher G. GoetzSource :
- Movement Disorders [ 0885-3185 ] ; 2010-07-15.
English descriptors
Abstract
Drug‐induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated “Recommended” if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. “Suggested” scales met two of the above criteria and those meeting one were “Listed.” Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang‐Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS‐26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS‐26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re‐ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23072
Links to Exploration step
ISTEX:D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><affiliation><mods:affiliation>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martínez-Martín">Pablo Martínez-Martín</name><affiliation><mods:affiliation>Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Fabbrini, Giovanni" sort="Fabbrini, Giovanni" uniqKey="Fabbrini G" first="Giovanni" last="Fabbrini">Giovanni Fabbrini</name><affiliation><mods:affiliation>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name><affiliation><mods:affiliation>Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI), Buenos Aires, Argentina</mods:affiliation></affiliation></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name><affiliation><mods:affiliation>The Movement Disorders Centre, University Health Network, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23072</idno><idno type="url">https://api.istex.fr/document/D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000775</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><affiliation><mods:affiliation>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martínez-Martín">Pablo Martínez-Martín</name><affiliation><mods:affiliation>Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Fabbrini, Giovanni" sort="Fabbrini, Giovanni" uniqKey="Fabbrini G" first="Giovanni" last="Fabbrini">Giovanni Fabbrini</name><affiliation><mods:affiliation>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name><affiliation><mods:affiliation>Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI), Buenos Aires, Argentina</mods:affiliation></affiliation></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name><affiliation><mods:affiliation>The Movement Disorders Centre, University Health Network, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-07-15">2010-07-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1131">1131</biblScope><biblScope unit="page" to="1142">1142</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5</idno><idno type="DOI">10.1002/mds.23072</idno><idno type="ArticleID">MDS23072</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clinimetrics</term><term>dyskinesia</term><term>rating scales</term><term>reliability</term><term>validity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Drug‐induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated “Recommended” if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. “Suggested” scales met two of the above criteria and those meeting one were “Listed.” Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang‐Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS‐26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS‐26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re‐ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Carlo Colosimo MD</name><affiliations><json:string>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</json:string></affiliations></json:item><json:item><name>Pablo Martínez‐Martín MD</name><affiliations><json:string>Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Giovanni Fabbrini MD</name><affiliations><json:string>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</json:string></affiliations></json:item><json:item><name>Robert A. Hauser MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Marcelo Merello MD, PhD</name><affiliations><json:string>Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI), Buenos Aires, Argentina</json:string></affiliations></json:item><json:item><name>Janis Miyasaki MD</name><affiliations><json:string>The Movement Disorders Centre, University Health Network, University of Toronto, Toronto, Canada</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD, PhD</name><affiliations><json:string>Department of Pharmacology, Faculdade de Medicina de Lisboa, Portugal</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD</name><affiliations><json:string>Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University, Toulouse, France</json:string></affiliations></json:item><json:item><name>Glenn T. Stebbins PhD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Anette Schrag MD, PhD</name><affiliations><json:string>Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinimetrics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rating scales</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>validity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>reliability</value></json:item></subject><articleId><json:string>MDS23072</json:string></articleId><language><json:string>eng</json:string></language><abstract>Drug‐induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated “Recommended” if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. “Suggested” scales met two of the above criteria and those meeting one were “Listed.” Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang‐Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS‐26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS‐26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re‐ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>2156</abstractCharCount><pdfWordCount>7592</pdfWordCount><pdfCharCount>48910</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>323</abstractWordCount></qualityIndicators><title>Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>12</total><last>1142</last><first>1131</first></pages><issn><json:string>0885-3185</json:string></issn><issue>9</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23072</json:string></doi><id>D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: The development of the UDysRS was supported by grants from the Michael J. Fox Foundation and EMD/Merck KGaA Pharmaceuticals. The Training Program was additionally supported by Santhera Pharmaceuticals. Final production, supplemental filming and editing expertise were provided by i3 Research, Inc. He has also consulted with Solvay Pharmaceuticals on the use of the UDysRS and Juvantia Pharmaceuticals and EMD/Merck KGaA in the development and analysis of data related to dyskinesia treatments.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations</title><author><persName><forename type="first">Carlo</forename><surname>Colosimo</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurological Sciences, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy</p></note><affiliation>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</affiliation></author><author><persName><forename type="first">Pablo</forename><surname>Martínez‐Martín</surname></persName><roleName type="degree">MD</roleName><affiliation>Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation></author><author><persName><forename type="first">Giovanni</forename><surname>Fabbrini</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</affiliation></author><author><persName><forename type="first">Robert A.</forename><surname>Hauser</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Marcelo</forename><surname>Merello</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI), Buenos Aires, Argentina</affiliation></author><author><persName><forename type="first">Janis</forename><surname>Miyasaki</surname></persName><roleName type="degree">MD</roleName><affiliation>The Movement Disorders Centre, University Health Network, University of Toronto, Toronto, Canada</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Portugal</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD</roleName><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University, Toulouse, France</affiliation></author><author><persName><forename type="first">Glenn T.</forename><surname>Stebbins</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Anette</forename><surname>Schrag</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-07-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1131">1131</biblScope><biblScope unit="page" to="1142">1142</biblScope></imprint></monogr><idno type="istex">D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5</idno><idno type="DOI">10.1002/mds.23072</idno><idno type="ArticleID">MDS23072</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Drug‐induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated “Recommended” if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. “Suggested” scales met two of the above criteria and those meeting one were “Listed.” Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang‐Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS‐26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS‐26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re‐ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>dyskinesia</term></item><item><term>Parkinson's disease</term></item><item><term>clinimetrics</term></item><item><term>rating scales</term></item><item><term>validity</term></item><item><term>reliability</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-06-02">Received</change><change when="2010-02-07">Registration</change><change when="2010-07-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="90"><doi origin="wiley" registered="yes">10.1002/mds.v25:9</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">9</numbering></numberingGroup><coverDate startDate="2010-07-15">15 July 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="40" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23072</doi><idGroup><id type="unit" value="MDS23072"></id></idGroup><countGroup><count type="pageTotal" number="12"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-06-02"></event><event type="manuscriptRevised" date="2010-01-13"></event><event type="manuscriptAccepted" date="2010-02-07"></event><event type="firstOnline" date="2010-03-22"></event><event type="publishedOnlineFinalForm" date="2010-07-19"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-03-22"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.8 mode:FullText" date="2011-05-03"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1131</numbering><numbering type="pageLast">1142</numbering></numberingGroup><correspondenceTo>Department of Neurological Sciences, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23072.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="31"></count><count type="wordTotal" number="8662"></count></countGroup><titleGroup><title type="main" xml:lang="en">Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations<link href="#fn1"></link></title><title type="short" xml:lang="en">Scales to Assess Dyskinesia in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Carlo</givenNames><familyName>Colosimo</familyName><degrees>MD</degrees></personName><contactDetails><email>carlo.colosimo@uniroma1.it</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Pablo</givenNames><familyName>Martínez‐Martín</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Giovanni</givenNames><familyName>Fabbrini</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Robert A.</givenNames><familyName>Hauser</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Marcelo</givenNames><familyName>Merello</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Janis</givenNames><familyName>Miyasaki</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Glenn T.</givenNames><familyName>Stebbins</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Anette</givenNames><familyName>Schrag</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="ES" type="organization"><unparsedAffiliation>Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="AR" type="organization"><unparsedAffiliation>Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI), Buenos Aires, Argentina</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="CA" type="organization"><unparsedAffiliation>The Movement Disorders Centre, University Health Network, University of Toronto, Toronto, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="PT" type="organization"><unparsedAffiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="GB" type="organization"><unparsedAffiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">dyskinesia</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">clinimetrics</keyword><keyword xml:id="kwd4">rating scales</keyword><keyword xml:id="kwd5">validity</keyword><keyword xml:id="kwd6">reliability</keyword></keywordGroup><supportingInformation><p> Supporting Information may be found in the online version of this article. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds23072:MDS_23072_sm_SupMaterial"></mediaResource><caption>Supplemental Material</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Drug‐induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated “Recommended” if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. “Suggested” scales met two of the above criteria and those meeting one were “Listed.” Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang‐Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS‐26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS‐26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re‐ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: The development of the UDysRS was supported by grants from the Michael J. Fox Foundation and EMD/Merck KGaA Pharmaceuticals. The Training Program was additionally supported by Santhera Pharmaceuticals. Final production, supplemental filming and editing expertise were provided by i3 Research, Inc. He has also consulted with Solvay Pharmaceuticals on the use of the UDysRS and Juvantia Pharmaceuticals and EMD/Merck KGaA in the development and analysis of data related to dyskinesia treatments.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Scales to Assess Dyskinesia in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations</title></titleInfo><name type="personal"><namePart type="given">Carlo</namePart><namePart type="family">Colosimo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</affiliation><description>Correspondence: Department of Neurological Sciences, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pablo</namePart><namePart type="family">Martínez‐Martín</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giovanni</namePart><namePart type="family">Fabbrini</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Hauser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marcelo</namePart><namePart type="family">Merello</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI), Buenos Aires, Argentina</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Janis</namePart><namePart type="family">Miyasaki</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Movement Disorders Centre, University Health Network, University of Toronto, Toronto, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenn T.</namePart><namePart type="family">Stebbins</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anette</namePart><namePart type="family">Schrag</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-07-15</dateIssued><dateCaptured encoding="w3cdtf">2009-06-02</dateCaptured><dateValid encoding="w3cdtf">2010-02-07</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">31</extent><extent unit="words">8662</extent></physicalDescription><abstract lang="en">Drug‐induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated “Recommended” if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. “Suggested” scales met two of the above criteria and those meeting one were “Listed.” Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang‐Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS‐26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS‐26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re‐ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: The development of the UDysRS was supported by grants from the Michael J. Fox Foundation and EMD/Merck KGaA Pharmaceuticals. The Training Program was additionally supported by Santhera Pharmaceuticals. Final production, supplemental filming and editing expertise were provided by i3 Research, Inc. He has also consulted with Solvay Pharmaceuticals on the use of the UDysRS and Juvantia Pharmaceuticals and EMD/Merck KGaA in the development and analysis of data related to dyskinesia treatments.</note><subject lang="en"><genre>Keywords</genre><topic>dyskinesia</topic><topic>Parkinson's disease</topic><topic>clinimetrics</topic><topic>rating scales</topic><topic>validity</topic><topic>reliability</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><note type="content"> Supporting Information may be found in the online version of this article.Supporting Info Item: Supplemental Material - </note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1131</start><end>1142</end><total>12</total></extent></part></relatedItem><identifier type="istex">D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5</identifier><identifier type="DOI">10.1002/mds.23072</identifier><identifier type="ArticleID">MDS23072</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000775 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000775 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:D08E3F2F1AF2C51B22125B2B3E968B6BFFC18FB5
|texte= Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations
}}
| This area was generated with Dilib version V0.6.23. |  |